

Resource Summary Report

Generated by [RRID](#) on Jul 30, 2026

Akt (pan) (40D4) Mouse mAb

RRID:AB_1147620

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 2920, RRID:AB_1147620

Antibody Information

URL: http://antibodyregistry.org/AB_1147620

Proper Citation: Cell Signaling Technology Cat# 2920, RRID:AB_1147620

Target Antigen: Akt (pan) (40D4) Mouse mAb

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: W, IP, IHC-P, IF-IC, F

Antibody Name: Akt (pan) (40D4) Mouse mAb

Description: This monoclonal targets Akt (pan) (40D4) Mouse mAb

Target Organism: rat, h, m, mouse, r, non-human primate, human, mk

Antibody ID: AB_1147620

Vendor: Cell Signaling Technology

Catalog Number: 2920

Alternative Catalog Numbers: 2920S

Record Creation Time: 20250819T214813+0000

Record Last Update: 20250820T000850+0000

Ratings and Alerts

No rating or validation information has been found for Akt (pan) (40D4) Mouse mAb.

No alerts have been found for Akt (pan) (40D4) Mouse mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 174 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Siegel F, et al. (2026) Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer. *Cancer discovery*, 16(1), 81.

Kral AJ, et al. (2026) Splice-switching ASOs targeting the AURKA 5' UTR collapse an SRSF1-AURKA-MYC oncogenic circuit in pancreatic cancer. *Molecular cell*, 86(1), 60.

Fan J, et al. (2026) PDX1 phosphorylation at S61 by mTORC1 links nutrient signaling to ? cell function and metabolic disease. *Cell reports*, 45(1), 116811.

Decker M, et al. (2025) In vivo validation of the palmitoylation cycle as a therapeutic target in NRAS-mutant cancer. *bioRxiv : the preprint server for biology*.

Müller-Schiffmann A, et al. (2025) Oxidized MIF is an Alzheimer's disease drug target relaying external risk factors to tau pathology. *Cell reports. Medicine*, 102520.

Dong Y, et al. (2025) Thyrotropin-releasing hormone protects hippocampal neurons against glutamate toxicity via phosphatidylinositol 3-kinase/AKT pathway and new protein synthesis. *bioRxiv : the preprint server for biology*.

Li M, et al. (2025) Aurora kinase A promotes trained immunity via regulation of endogenous S-adenosylmethionine metabolism. *eLife*, 14.

Dause TJ, et al. (2025) Intracrine VEGF Signaling Is Required for Adult Hippocampal Neural Stem Cell Maintenance and Vascular Proximity. *Molecular neurobiology*, 62(8), 9604.

Wang X, et al. (2025) Cell-specific Nav1.6 knockdown reduced astrocyte-derived A β by reverse Na $^{+}$ -Ca $^{2+}$ transporter-mediated autophagy in alzheimer-like mice. *Journal of advanced research*, 72, 451.

Wang Q, et al. (2025) FGF-induced phospholipase C β signaling regulates lacrimal gland branching by competing with PI3K in phosphoinositide metabolism. *Cell reports*, 44(8), 116046.

Omale S, et al. (2025) Assessment of distinct effects of *Parinari curatellifolia* Planch.ex Benth Ethanolic leaf extract on glucose transport in different cell types. *PeerJ*, 13, e20269.

Tomlinson PR, et al. (2025) Paradoxical dominant negative activity of an immunodeficiency-associated activating PIK3R1 variant. *eLife*, 13.

Dacheux MA, et al. (2025) BRAFV600E-Driven Lung Tumorigenesis Requires Ligand-Mediated Activation of ERBB Receptor Signaling. *bioRxiv : the preprint server for biology*.

Wimer LA, et al. (2025) Glycation-lowering compounds inhibit ghrelin signaling to reduce food intake, lower insulin resistance, and extend lifespan. *Cell reports*, 44(10), 116422.

Wang X, et al. (2025) Tuning insulin receptor signaling using de novo-designed agonists. *Molecular cell*, 85(21), 4064.

Ko HM, et al. (2025) Liprin- γ 1 enhances PHLDB3 oncogenic function in colorectal cancer via activation of mTORC2-AKT1 pathway. *Cell reports*, 45(1), 116722.

Soteriou C, et al. (2025) Two cooperative lipid binding sites within the pleckstrin homology domain are necessary for AKT binding and stabilization to the plasma membrane. *Structure (London, England : 1993)*, 33(1), 181.

Matkar S, et al. (2025) Kinome Reprogramming of G2/M Kinases and Repression of MYCN Contribute to Superior Efficacy of Lorlatinib in ALK-Driven Neuroblastoma. *Molecular cancer therapeutics*, 24(9), 1389.

Choi J, et al. (2024) Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas. *Cancer cell*, 42(5), 833.

Goedeke L, et al. (2024) High-fat-diet-induced hepatic insulin resistance per se attenuates murine de novo lipogenesis. *iScience*, 27(11), 111175.